Latest Hotspot

Sutro Biopharma Begins Phase 2 REFRαME-L1 Study on Luvelta for Non-Small Cell Lung Cancer Patients

26 August 2024
3 min read

Sutro Biopharma, Inc. (referred to as Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology firm innovating in site-specific and novel-format antibody drug conjugates (ADCs), announced that the global Phase 2 trial named REFRαME-L1 for luveltamab tazevibulin (luvelta) in non-small cell lung cancer (NSCLC) patients expressing Folate Receptor-α (FRα) has commenced and is now enrolling participants. Preliminary results from this trial are anticipated in the first half of 2025.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序

描述已自动生成

“The launch of REFRαME-L1 marks a significant step in expanding the use of luvelta for a broader patient population with FRα expressing cancers. We have amassed strong preclinical evidence that luvelta may offer a vital new treatment option for NSCLC, supported by its precise engineering, ample therapeutic window, and capability to treat patients with lower FRα expression levels,” stated Anne Borgman, M.D., Sutro’s Chief Medical Officer.

Lung cancer remains the primary cause of cancer-related deaths globally. Over half of these patients receive a metastatic diagnosis, resulting in a 5-year survival rate as low as 8%. Despite the availability of various treatment options, most advanced NSCLC patients eventually develop resistance and face fewer treatment alternatives as their disease advances.

FRα is present in several cancer types, including NSCLC, but has minimal expression in normal tissues. Around 30% of adenocarcinoma NSCLC patients exhibit FRα expression, making FRα an appealing therapeutic target for treating advanced NSCLC and offering these patients a chance for targeted therapy.

REFRαME-L1 is a Phase 2 clinical trial designed to assess the safety and efficacy of luvelta in adults with previously treated advanced or metastatic NSCLC with FRα expression of 25% Tumor Proportion Score (TPS). The trial plans to administer doses of 4.3 mg/kg of luvelta every three weeks.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of August 26, 2024, there are 77 investigational drugs for the FOLR1 target, including 104 indications, 76 R&D institutions involved, with related clinical trials reaching 144, and as many as 6945 patents.

Luveltamab Tazevibulin, an Antibody Drug Conjugate (ADC) designed to target FOLR1, has demonstrated promise in multiple therapeutic domains, including oncology, endocrinology and metabolic disorders, urogenital conditions, gastrointestinal issues, hematologic and lymphatic disorders, as well as respiratory ailments. This drug is being actively pursued for several cancers such as fallopian tube carcinoma, ovarian epithelial carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, recurrent platinum-resistant ovarian carcinoma, metastatic non-small cell lung cancer, stage IIIB non-small cell lung cancer, advanced malignant solid tumors, endometrial carcinoma, primary peritoneal carcinoma, endometrioid carcinoma, acute myeloid leukemia, adenocarcinoma, non-small cell lung cancer, and various other solid tumors.

图形用户界面, 文本, 应用程序

描述已自动生成

Monopar Gets Approval to Start Phase 1 Trial of New Radiopharmaceutical for Advanced Cancers
Latest Hotspot
3 min read
Monopar Gets Approval to Start Phase 1 Trial of New Radiopharmaceutical for Advanced Cancers
26 August 2024
Monopar Therapeutics revealed that it has obtained Human Research Ethics Committee (HREC) approval in Australia to initiate a Phase 1 clinical trial for its innovative radiopharmaceutical MNPR-101-Lu.
Read →
Global New Drug Research and Development Progress Weekly Report (8.19-8.25)
Drug Highlight
15 min read
Global New Drug Research and Development Progress Weekly Report (8.19-8.25)
26 August 2024
8.19-8.25 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Read →
D&D Pharmatech Initiates Phase 2 Trial of DD01 for Obesity-Related MASLD/MASH Treatment
Latest Hotspot
4 min read
D&D Pharmatech Initiates Phase 2 Trial of DD01 for Obesity-Related MASLD/MASH Treatment
23 August 2024
D&D Pharmatech begins Phase 2 trial for DD01, a long-lasting dual GLP-1/Glucagon receptor agonist, to assess its safety and efficacy in overweight/obese individuals with MASLD/MASH.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 23
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 23
23 August 2024
Aug 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.